Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
CA 2440461 C · Owner: Agensys, Inc. · Inventors: Hubert, Rene S.; Challita-Eid, Pia M.; Morrison, Karen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel gene (designated 161P5C5) and its encoded protein and variants , thereof, are described wherein 161P5C5 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P5C5 provides a diagnostic prognostic, prophylactic , and/or therapeutic target for cancer. The 161P5C5 gene or fragment thereof or , its encoded protein, or variants thereof or a fragment thereof, can be used , to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P5C5 can be used in active or passive immunization.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 9, 2002 and granted November 29, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 9, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 9, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.